AlphAIAlphAI — Financial news for AI agents
simplywall.stOCT 62 min read

What Glaukos Holders Were Betting On All Along

Glaukos (GKOS) shares rose 89.3% over the past year, driven by strong adoption of iDose TR and Epioxa. Q2 2026 revenue was $185.61M, up from $124.12M a year earlier, with management raising 2026 sales guidance. The company reported a loss of $18.38M and a declining net margin of 9.9%. Analysts remain divided on its future, with optimistic and cautious Fair Value estimates at $123 and $74.28, respectively.

Original reporting
simplywall.st
Published Oct 6, 2026, 5:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 5:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Glaukos Holders Were Betting On All Along — source image
Source · simplywall.st
Decision brief

The 30-second read

Low
01

Why it matters

First disclosure of Q2 results and guidance raise provides fresh data for valuation models.

02

Market read

New earnings data and guidance lift could prompt short-term price movement.

03

What to watch

Potential regulatory scrutiny on pricing and long-term profitability of iDose TR.

Relevance 4/10Novelty 4/10Timing: post-market today

Background

The article reviews Glaukos' recent performance and valuation narratives.

Market effects

Sector

Positive outlook for ocular therapy sector as iDose TR adoption accelerates.

Regional

U.S. ophthalmic device market may see increased investor interest.

Global

Limited to healthcare investors, no broad market effect.

Counterpoint

What could challenge this read

Reimbursement cuts and competition could limit upside despite guidance lift.

Key entities

  • company
    Glaukos Corporation

    U.S.-listed ophthalmic device maker.

Read at source← All news

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min